NCT07365410 2026-01-26
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
Clinical Trials
12 trialsNCT07348965 2026-01-16
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Guangzhou University of Traditional Chinese Medicine
Phase NA Not yet recruiting
NCT07314216 2026-01-06
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
Hunan Cancer Hospital
Phase 2 Not yet recruiting
NCT07193160 2025-09-25
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
Fudan University
Phase 2 Not yet recruiting
NCT06868732 2025-03-11
Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1 Not yet recruiting
NCT06537297 2024-09-20
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
NCT06585644 2024-09-05
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT06483672 2024-07-03
LungBrain001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06452433 2024-06-11
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06319950 2024-03-20
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Taizhou Hospital
Phase 2 Not yet recruiting
NCT06117644 2023-11-07
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Not yet recruiting
NCT04965831 2021-07-16
Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting